| 刘莹,罗国帅,乔义德,等.尼可地尔联合替罗非班对急性 ST段抬高型心肌梗死急诊经皮冠状动脉介入治疗术后的影响[J].安徽医药,2024,28(8):1645-1649. |
| 尼可地尔联合替罗非班对急性 ST段抬高型心肌梗死急诊经皮冠状动脉介入治疗术后的影响 |
| Effect of nicorandil combined with tirofiban on patients with acute ST-segment elevation myocardial infarction after emergency percutaneous coronary intervention |
| |
| DOI：10.3969/j.issn.1009-6469.2024.08.035 |
| 中文关键词: ST段抬高型心肌梗死 尼可地尔 替罗非班 左心室重构 缺血再灌注损伤 经皮冠状动脉介入治疗 |
| 英文关键词: ST elevation myocardial infarction Nicorandil Tirofiban Left ventricular remodeling Ischemia-reperfusion inju- ry Percutaneous coronary intervention |
| 基金项目:河南省卫生健康委员会资助项目( LHGJ20191466) |
|
| 摘要点击次数: 621 |
| 全文下载次数: 384 |
| 中文摘要: |
| 目的探讨尼可地尔联合替罗非班对急性 ST段抬高型心肌梗死( STEMI)急诊经皮冠状动脉介入治疗( PCI)术后的影响。方法选取 2018年 5月至 2022年 5月于南阳医学高等专科学校附属中医院治疗的 100例 STEMI急诊 PCI病人为研究对象，采用随机数字表法分为对照组和治疗组，各 50例。对照组给予替罗非班治疗，治疗组给予尼可地尔 +替罗非班治疗，对比两组治疗后 TIMI帧数( CTFC)、 TIMI血流分级、丙二醛(MDA)白细胞介素 -6(IL-6)、肿瘤坏死因子 -α(TNF-α)、左心室射血分数(LVEF)、左心室收缩末期内径( LVESD)、左心室舒张末期内径(、LVEDD)的变化情况。结果术后即刻，治疗组 CTFC低于对照组［(21.36±3.46)帧比( 27.52±3.63)帧］(P<0.05)TIMI血流分级高于对照组［(2.89±0.41)级比( 2.61±0.37)级］(P<0.05)；术后 4周，治疗组 LVEDD［( 47.32±5.25)mm比( 53.12±6.79，)mm］、 LVESD水平［( 27.58±5.26)mm比( 31.24±6.31)mm］低于对照组( P<0.05)LVEF高于对照组［( 56.37±6.98)%比( 49.79±6.02)%］(P<0.05)；术后 48 h，治疗组病人 MDA、IL-6、TNF-α水平低于对照(P<005)；协方差主体间效应检验显示两组术后上述指标均差异有统计学意义( P<0.05)；术后即刻，治疗组无复流或慢血流生率低于对照组( P<0.05)；随访 2个月，治疗组病人不良事件发生率低于对照组( P<0.05)。结论采用尼可地尔联合替罗.，发组非班对 STEMI急诊 PCI病人进行治疗，能够改善病人左心室重构，减少缺血再灌注损伤，且安全性高。 |
| 英文摘要: |
| Objective To investigate the effect of nicorandil combined with tirofiban on patients with acute ST-segment elevation myocardial infarction (STEMI) after emergency percutaneous coronary intervention (PCI).Methods One hundred patients with STEMIemergency PCI who were treated in the Affiliated Hospital of Traditional Chinese Medicine of Nanyang Medical College from May 2018to May 2022 were regarded as the research objects, and they were assigned into the control group and the treatment group by randomnumber table method, with 50 cases in each group. The control group were treated with tirofiban, and the treatment group were treatedwith nicorandil + tirofiban. The changes in TIMI frame count (CTFC), TIMI blood flow grade, malondialdehyde (MDA), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), and left ventricular end-diastolic diameter (LVEDD) were compared.Results Immediately after surgery, the CTFC in the treatment group after treatment was lower than that in the control group [(21.36±3.46) vs. (27.52±3.63)] (P<0.05), the TIMI blood flow classification was higher than that in the control group [(2.89±0.41) vs. (2.61±0.37)] (P<0.05); 4 weeks after surgery, the levels of LVEDD [(47.32±5.25) mm vs. (53.12±6.79) mm] and LVESD [(27.58±5.26) mm vs. (31.24±6.31) mm] in the treatment group were lower than those in the con- trol group (all P<0.05), LVEF in the treatment group was higher than that in the control group [(56.37±6.98)% vs. (49.79±6.02)%] (P< 0.05); 48 hours after surgery, the levels of MDA, IL-6 and TNF-α in the treatment group were lower than those in the control group (all P<0.05). The between-subject effect of covariance test showed that there were differences in the above indicators between the twogroups after operation (all P<0.05). Immediately after operation, the incidence of no-reflow or slow flow in the treatment group was low- er than that in the control group (P<0.05); during the 2-month follow-up, the incidence of adverse events in the treatment group was less than that in the control group (P<0.05).Conclusion The use of nicorandil combined with tirofiban for STEMI patients with emergencyPCI can ameliorate left ventricular remodeling and reduce ischemia-reperfusion injury with high safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
